Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) CEO Kevin Koch sold 3,152 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $18.91, for a total value of $59,604.32. Following the completion of the transaction, the chief executive officer now directly owns 14,478 shares of the company’s stock, valued at $273,778.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Edgewise Therapeutics Stock Up 1.2 %
NASDAQ EWTX opened at $19.52 on Monday. The firm’s 50 day moving average is $16.90 and its 200-day moving average is $12.80. The company has a market capitalization of $1.82 billion, a PE ratio of -12.35 and a beta of 0.15. Edgewise Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $20.90.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.03). As a group, sell-side analysts expect that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current year.
Institutional Trading of Edgewise Therapeutics
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Edgewise Therapeutics in a research report on Tuesday, April 16th. Truist Financial reiterated a “buy” rating and issued a $25.00 price target on shares of Edgewise Therapeutics in a report on Wednesday, April 17th. Royal Bank of Canada raised their price objective on shares of Edgewise Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, April 22nd. Finally, Piper Sandler assumed coverage on shares of Edgewise Therapeutics in a research note on Thursday, March 7th. They issued an “overweight” rating and a $48.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $31.20.
Read Our Latest Research Report on EWTX
Edgewise Therapeutics Company Profile
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
See Also
- Five stocks we like better than Edgewise Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 4/29 – 5/3
- The Role Economic Reports Play in a Successful Investment Strategy
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to invest in marijuana stocks in 7 steps
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.